News
Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story....
Say What? 2 New Studies Find Little Evidence That Marijuana Helps Treat Chronic Pain and PTSD
When it comes to growth industries, essentially nothing tops legal marijuana. According to cannabis research firm ArcView, the legal cannabis market in North America is slated to grow from $6.9....
Why Adamas Pharmaceuticals Inc Stock Skyrocketed Today
Shares of Adamas Pharmaceuticals (NASDAQ: ADMS) have skyrocketed today, up 42.3% as of 12:02 p.m. EDT, after the company announced yesterday evening that the Food and Drug Administration approved....
3 Top Healthcare Stocks to Buy Now
It's been a good year for healthcare stocks in general, but a handful of quality companies haven't been swept upward with the rest of the sector. Allergan plc (NYSE: AGN) and CVS Health Corp.....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
Here's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy)
Over the past two years, only a small handful of publicly traded companies have the distinction of losing more than 90% of their value. Drugmaker Valeant Pharmaceuticals (NYSE: VRX) finds itself....
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much
Two members of the U.S. House of Representatives Committee on Oversight and Government Reform want to know why the prices of multiple sclerosis (MS) drugs are so high. Rep. Elijah Cummings (D-Md.)....
Why Ultragenyx Pharmaceutical Stock Is Sinking Today
Shares of the rare-disease drugmaker Ultragenyx Pharmaceutical (NASDAQ: RARE) are under pressure today after the company announced that its late-stage study assessing aceneuramic acid extended....
Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
Shares of clinical-stage biopharma Paratek Pharmaceuticals (NASDAQ: PRTK) soared 37% today after news leaked that the company is considering a sale.The stock has returned solid gains to investors....
Why Intra-Cellular Therapies Is Skyrocketing Today
Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage biopharma focused on diseases of the central nervous system, rose more than 26% as of 11:35 a.m. EDT Wednesday. The big jump came in....
2 Marijuana Stocks That Have Imploded Since August Began
In many ways, the legal marijuana industry could be described as the greatest thing since sliced bread for investors. Over the trailing one-year period, the average marijuana stock has increased....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
3 Top Small-Cap Stocks to Buy in August
Small-cap stocks, or those with a market cap of between $300 million and $2 billion, often get a bad rap on Wall Street. Smaller companies are typically viewed as having untested business models,....
A Record Number of Americans Have Tried Marijuana, New Survey Shows
Marijuana: it was once a taboo topic, but is no longer.According to a newly released study from national pollster Gallup, more Americans than ever have tried marijuana.Gallup has been sporadically....
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE: PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly type of leukemia. The approval....